المؤلفون: von Glahn, U. H., Povolny, J. H.

المصدر: SAE Transactions, 1958 Jan 01. 66, 620-629.

الوصول الحر: https://www.jstor.org/stable/44554184Test

المؤلفون: James, Wp, Caterson, Id, Coutinho, W, Finer, N, VAN GAAL LF, Maggioni, Ap, TORP-PEDERSEN, C, Sharma, Am, Shepherd, Gm, Rode, Ra, Renz, Cl, Van Gaal LF, Torp-Pedersen, C, Pepine, C, Pocock, S, Drexler, H, Swedberg, K, Sleight, P, Armstrong, P, Kerr, D, Dagenais, G, Brophy, J, Avezum, A, Bogaty, P, Fabbri, G, Galli, M, Hildebrandt, P, Mann, J, Ostergren, J, Sherman, D, Zannad, F, Colquhoun, D, Hollanders, G, e Forti A, Costa, Cifkova, R, Toubro, S, Ziegler, O, Scherbaum, Wa, Jordan, J, Halmy, L, Ferrannini, E, Santini, F, Gonzalez, C, Narkiewicz, K, Hancu, N, Payer, J, Pascual, J, Wilding, J, Campbell, L, Carey, D, Gerstman, M, Karrasch, J, Lefkovits, J, Marks, J, Marks, S, Moses, R, Phillips, P, Proietto, J, Roberts, D, Roberts-Thomson, P, Shaw, J, Simpson, R, Singh, B, Singleton Jeffries, W, Stuckey, B, Boland, J, Brohet, C, Coucke, F, Dendale, P, Jouret, G, Kolanowski, J, Kutnowski, M, Martens, F, Muls, E, Peiffer, F, Penninckx, H, Scheen, A, Schoors, D, Vaerenberg, M, Van Cleemput, J, Van Crombrugge, P, Van Kuyk, M, Verhaegen, A, Wollaert, B, de Albuquerque DC, Appolinario, J, de Godoy Matos AF, Gross, Jl, Halpern, A, Kerr Saraiva JF, Milagres, R, Repetto, G, Suplicy, Hl, Zanella, Mt, Bednarova, J, Cepelak, V, Cerny, P, Hainer, V, Havranek, P, Homza, M, Jansa, P, Karlicek, M, Kolesar, J, Kotik, I, Kucera, D, Kuchar, J, Kunc, M, Kvapil, M, Linhart, A, Machova, V, Matuska, J, Oral, I, Pavlas, J, Pesatova, S, Povolny, J, Semrad, B, Smetana, K, Soucek, M, Svacina, S, Tesinsky, P, Urbanek, R, Wasserburger, B, Zachoval, R, Zahumensky, E, Zidkova, E, Astrup, A, Dominguez, H, Faber, J, Hilderbrant, P, Kober, L, Perrild, H, Richelsen, B, Sogaard, P, Svendsen, Ol, Urhammer, S, Archambeaud, F, Basdevant, A, Borys, Jm, Bringer, J, Brunetiere, C, Charpentier, G, Cocaul-André, M, Dabadie, H, Dubreuil, A, Estour, B, Gautier, Jf, Gibault, T, Halimi, S, Hespel, Jp, Issa Sayegh, M, Krempf, M, Laville, M, Lecerf, Jm, Louvet, Jp, Penfornis, A, Ritz, P, Schlienger, Jl, Schmitt, B, Valensi, P, Baar, M, Beermann, J, Bock, M, Boenner, G, Dammann, Hg, Diehm, C, Ditschuneit, H, Gadow, J, Gehlhar, S, Gessner, S, Guthersohn, A, Hamann, A, Hanefeld, M, Hasenfuss, G, Herzner, A, Heun, Kc, Heufelder, Ae, Hohensee, H, Jacob, S, Krings, P, Krätzig, B, Krosse, B, Lehmann, Rt, Mindt-Prüfert, S, Maisch, B, Pfeiffer, Af, Richard, F, Rose, B, Schmidt, E, Scholze, J, Schreckenberg, A, Stuebler, P, Walter, J, Wirth, A, Wunderlich, J, Abraham, G, Altorjay, A, Augusztin, G, Csaszar, A, Czuriga, I, Dinnyes, J, Gero, L, Gyimesi, A, Janosi, A, Kovacs, I, Liziczai, I, Majtenyi, A, Medvegy, M, Nadhazi, Z, Pados, G, Polak, G, Ronaszeki, A, Sido, Z, Simon, K, Anzà, C, Bevilacqua, M, Bosello, O, Chiariello, M, Cordera, R, Ferrari, E, Frittitta, L, Giorgino, R, Liuzzi, A, Malinverni, C, Di Mario, U, Melchionda, N, Occhi, G, Perticone, F, Pinchera, A, Pinelli, G, Rovera, G, Santeusanio, F, Urbinati, S, Alpizar-Salazar, M, Carrillo-Ortega, E, Fanghanel Salmon, G, Laviada-Molina, Ha, Madero, Ma, Rodriguez, G, Saldate, C, Sanchez-Castillo, Cp, Violante, Rm, Wacher, N, Zayas-Jaime, Fj, Zuniga-Guajardo, S, Adamiec, R, Banasiak, W, Chrusciel, P, Derlaga, B, Gebala, A, Gessek, J, Janik, K, Janion, M, Kalina, Z, Kozlowski, A, Kusnierz, B, Majcher, Z, Miekus, P, Niegowska, J, Okopien, B, Ostrowska, L, Pasowicz, M, Piepiorka, M, Pluta, W, Polaszewska-Muszynska, M, Ponikowski, P, Pupek-Musialik, D, Sawicki, A, Sobocik, H, Stankiewicz, A, Szpajer, M, Trojnar, R, Tykarski, A, Wrabec, K, Wyrzkowski, B, Zahorska-Markiewicz, B, Zalewski, M, Carrageta, M, Mendes Pedro MM, Parente Martins LM, dos Santos, L, Babes, A, Creteanu, G, Dan, Ga, Dragulescu, Si, Graur, M, Tirgoviste, Ci, Morosanu, M, Mota, M, Paveliu, Fs, Radoi, M, Ranetti, A, Totoian, I, Andre, I, Bugan, V, Cencarik, J, Csala, L, Farsky, S, Gonsorcik, J, Kamensky, G, Kmec, J, Krahulec, B, Kurian, R, Macek, V, Majercak, I, Micko, K, Mokan, M, Riecansky, I, Sojka, G, Uhliar, R, Urgeova, L, Vancik, J, Baro, Fm, Barrios Merino, A, Borras, Jl, Caixas, A, Cuatrecasas Cambra, G, Dominguez Escribano JR, Duran Garcia, S, Escobar-Jimenez, L, Esteva de Antonio, I, Formiguera Sala, X, Garcia-Luna, Pp, Garcia Robles, R, Gonzalez Albarran, O, Hernandez-Mijares, A, Martin Hidalgo, A, Masmiquel Comas, L, Morales Perez, F, Moreno Esteban, B, Pascual Izuel JM, Redon Mas, J, Ricart, W, Rubio, Ma, Ruilope, Lm, Salas-Salvado, J, Terroba Larumbe, M, Tinahones, F, de la Torre Casares ML, Vidal Cortada, J, Zuniga-Perez Lemaur, M, Abdulhakim, Ee, Adler, A, Barnett, Ah, Bodmer, C, Campbell, Iw, Chowdhury, T, Cleland, J, Cook, Rc, Dinneen, S, Donnachie, H, Haslam, Dw, Hillis, Gs, Horne, M, Howarth, Dj, Hughes, E, Jackson, S, Jones, Sc, Jones, Th, Kumar, S, Lean, M, Maroni, J, Mcinnes, G, Middleton, A, Morris, A, Newcombe, G, O'Kane, Kp, Pavel, Ic, Pawa, R, Perry, C, Pitts, C, Raja, A, Reckless, J, Robinson, J, Sarmiento, R, Soo, Sc, Taylor, S, Thomas, Ho, Thomson, Ma, Wilkins, M.

المصدر: The New England journal of medicine
James, W P T, Caterson, I D, Coutinho, W, Finer, N, Van Gaal, L F, Maggioni, A P, Torp-Pedersen, C T, Sharma, A M, Shepherd, G M, Rode, R A, Renz, C L, SCOUT Investigators & Richelsen, B 2010, ' Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects ', Briefings from the New England Journal of Medicine, vol. 363, no. 10, pp. 905-17 . https://doi.org/10.1056/NEJMoa1003114Test

مصطلحات موضوعية: Male, medicine.medical_specialty, Myocardial Infarction, Blood Pressure, Kaplan-Meier Estimate, Type 2 diabetes, Klinikai orvostudományok, Placebo, law.invention, Double-Blind Method, Randomized controlled trial, Weight loss, law, Internal medicine, Appetite Depressants, medicine, Humans, Obesity, Myocardial infarction, Stroke, Aged, business.industry, Hazard ratio, Orvostudományok, General Medicine, Middle Aged, Overweight, medicine.disease, Surgery, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Cardiology, Female, Human medicine, medicine.symptom, business, Cyclobutanes, Sibutramine, medicine.drug

الوصف: Background The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. Methods We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). Results The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. Conclusions Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4edf26f01abf50ec8934da065b8ce86eTest
https://doi.org/10.1056/nejmoa1003114Test

المؤلفون: Graham, Susan, Ye, Siqin, Qian, Min, Sanford, Alexandra R, Di Tullio, Marco R, Sacco, Ralph L, Mann, Douglas L, Levin, Bruce, Pullicino, Patrick M, Freudenberger, Ronald S, Teerlink, John R, Mohr, J P, Labovitz, Arthur J, Lip, Gregory Y H, Estol, Conrado J, Lok, Dirk J, Ponikowski, Piotr, Anker, Stefan D, Thompson, John L P, Homma, Shunichi, WARCEF Investigators, Homma, S, Thompson, J L P, Pullicino, P, Freudenberger, R, Graham, S, Teerlink, J, Ammon, S, Mann, D, Sacco, R L, Massie, B, Anker, S, Labovitz, A, Moy, C, Gilbert, P, Gutmann, L, Marler, J, Mejia, V, Gabriel, A, Czaja, P, Gaciong, Z, Gora, J, Kleinrok, A, Prokop-Lewicka, G, Haddad, H, Davies, R, Sitwell, L, Donaldson, J, To, T, Yufe, R, Donelly, B, Huynh, T, Cote, R, St Jacques, B, Borts, D, Tullio, G, Sindilar, A M, Winder, T, Janzen, E, Walker, C, Moe, G, Bayer, N, Konig, A, Arnold, M, Spence, D, Smith, J, Bessoudo, R, Bailey, P, McNulty, A, Nawaz, S, Dewar, C, Rajda, M, MacFarlane, M, Minuk, J, Schanz, C, Penn, A, Atkins, L, Ducharme, A, Brown, H, Zieroth, S, Muñoz, A, Lok, D, ten Holter, J B M, Huls, C, Bruggink-Andre, P, van Bujisen-Nutters, A, Ziekenhuis, Daniels, M, Coppes, A, van Zagten, M, Elzebroek, N, Hamroui, K, de Kort, P L M, Vuijsters, J, Holwerda, N, Hermans, W, van der Loo, R, Wajon, E, Hageman, G, Buchem-Damming, G v, Ronner, E, Wissenburg-van Lieshout, A, Niekus, H, van Hessen, M W J, Verheul, G A M, Linssen, G, te Pas, L, Plomp, J, de Milliano, P A R, Breedveld, R, Bos, M J, Houra, M, Beran, D, Lebedova, R, Carda, J, Bednarova, E, Vosmerova, J, Marcinek, G, Drasnar, T, Najmanova, O, Dunaj, M, Pechackova, E, Kuchar, M, Jansky, P, Simon, J, Dvorakova, H, Gregor, P, Maruskova, M, Svoboda, L, Lorenc, Z, Kralicek, P, Pollak, L, Krobot, M, Spinar, J, Nemec, M, Spinarova, L, Kuba, R, Padour, F, Padourova, I, Padour, M, Michalova, M, Golan, L, Hajkova, M, Povolny, J, Krizova, L, Horak, D, Kucera, P, Malek, I, Krizova, B, Svoboda, J, Ferkl, R, Regos, L, Csuros, L, Lovasz, O, Kiss, G, Timar, S, Torok, N, Hajnalne, A, Palossy, B, Nagy, A, Fulop, P, Jakab, G, Ronaszeki, A, Bodi, M, Satori, M, Edes, I, Varga, I, Kovacs, A, Berente, L, Péterfai, E, Pauer, R, Toth, K, Nagy, E, Benczur, B, Karsay, K, Végh, T, Nagy, R, Karpati, P, Davidovits, Z, Borbola, J, Vanyi, J, Oze, B, Bujdoso, A, Kosa, I, Baliko, L, Natour, M, Morgil, M, Hartmann, E, Morgil, H, Winkler, R, Gass, S, Baumann, S, Jeserich, M, Rodl, J, Dzaiy, M, Turhan, G, Wolf, K, Genth-Zotz, S, Siebert, T, Jakobs, C, Kiorwantsi, M, Pieske, B, Wachter, R, Schoenauer, M, Voigt, S, Schunkert, H, Boguschewski, A, Resch, M, Wensel, R, Schumann, V, Heidrich, P, Girina, O, Prokopovych, Y, Lebedynska, M, Sorokina, I, Karpenko, O, Brodi, N, Klochkov, S, Voronkov, L, Besaga, Y, Novikova, O, Amosova, K, Yaremenko, O, Balaban, K, Kovalenko, V, Polenova, N, Sakharchuk, I, Ogorodnichuk, A, Rudenko, L, Tutov, Y, Parkhomenko, A, Kozhukhov, S, Yakimenko, E, Kolomiets, S, Yurlov, V, Tikhonova, S, Estol, C, Elizalde, A, Mangariello, B, Zaidman, C, Guerlloy, F, Gitelman, P, Crotto, K, Sassone, S, Aiub, J, Novoa, F, Lopez Santi, R, Romia, P, Montaña, O, Malchik, D, F Sokn, Schygiel, P, Porcile, R, Soria Tito, F, Thierer, J, Avellana, P, Rapallo, C, Calderon, M, MacFadyen, R, Haynes, R, Partridge, J, Dérera, L, Kokles, M, Mehe?ová, S, Zachar, A, Hranai, M, Varadyova, T, Göbö, T, Litvinova, J, Loviska, P

المساهمون: Klinik für Herz- und Kreislauferkrankungen

مصطلحات موضوعية: info:eu-repo/classification/ddc

الوصف: We sought to determine whether cognitive function in stable outpatients with heart failure (HF) is affected by HF severity. A retrospective, cross-sectional analysis was performed using data from 2, 043 outpatients with systolic HF and without prior stroke enrolled in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. Multivariable regression analysis was used to assess the relationship between cognitive function measured using the Mini-Mental Status Exam (MMSE) and markers of HF severity (left ventricular ejection fraction [LVEF], New York Heart Association [NYHA] functional class, and 6-minute walk distance). The mean (SD) for the MMSE was 28.6 (2.0), with 64 (3.1%) of the 2,043 patients meeting the cut-off of MMSE<24 that indicates need for further evaluation of cognitive impairment. After adjustment for demographic and clinical covariates, 6-minute walk distance (?-coefficient 0.002, p<0.0001), but not LVEF or NYHA functional class, was independently associated with the MMSE as a continuous measure. Age, education, smoking status, body mass index, and hemoglobin level were also independently associated with the MMSE. In conclusion, six-minute walk distance, but not LVEF or NYHA functional class, was an important predictor of cognitive function in ambulatory patients with systolic heart failure.

العلاقة: https://mediatum.ub.tum.de/1328069Test

الإتاحة: https://mediatum.ub.tum.de/1328069Test

المؤلفون: Fox, KM, Bertrand, M, Ferrari, R, Remme, WJ, Simoons, ML, Simoons, M, Bassand, JP, Aldershvile, J, Hildebrandt, P, Cokkinos, D, Toutouzas, P, Eha, J, Erhardt, L, Erikssen, J, Grybauskas, P, Kalnins, U, Karsch, K, Sechtem, U, Keltai, M, Klein, W, Lüscher, T, Mulcahy, D, Nieminen, M, Oto, A, Ozsaruhan, O, Paulus, W, Providencia, L, Riecansky, I, Ruzyllo, W, Santini, U, Tavazzi, L, Soler-Soler, J, Widimsky, P, Julian, D, Dargie, H, Murray, G, Kübler, W, Thygesen, K, Duprez, D, Steg, G, Drexel, H, Gombotz, G, Heyndrickx, GH, Legrand, V, Materne, P, Van Mieghem, W, Bocek, P, Branny, M, Cech, M, Charouzek, J, Drazka, J, Fabik, L, Florian, J, Francek, L, Groch, L, Havranek, P, Hradec, J, Jansky, P, Jirmar, R, Jokl, I, Krejcova, H, Kvasnak, M, Maratka, T, Marcinek, G, Moravcova, J, Nedbal, P, Peterka, K, Povolny, J, Rosolova, H, Semrad, B, Sochor, K, Spacek, R, Spinar, J, Stipal, R, Stuchlik, K, Sulda, M, Ulman, J, Vaclavicek, A, Vojtisek, P, Bjerregaard-Andersen, H, Kristensen, K, Madsen, JK, Markenvard, J, Meibom, J, Norgaard, A, Scheibel, M, Leht, A, Teesalu, R, Vahula, V, Itkonen, A, Juvonen, J, Karmakoski, J, Kilkki, E, Koskela, E, Melin, J, Nieminen, MS, Savola, R, Terho, T, Voipio-Pulkki, LM, Apffel, F, Attali, P, Barjhoux, C, Baron, B, Berthier, Y, Dambrine, P, Decoulx, E, Deshayes, P, Fouche, R, Genest, M, Godard, S, Guillot, JP, Hanania, G, Khattar, P, Leroy, F, Mansourati, J, Piquemal, R, Quiret, JC, Raynaud, P, Rondepierre, D, Roynard, JL, Sudhibhasilp, S, Van Belle, E, Bilbal, A, Lauer, B, Rettig-Stürmer, G, Riessen, R, Rutsch, W, Sigel, HA, Simon, R, Von Schacky, C, Winkelmann, BR, Avgeropoulou, C, Christakos, S, Feggos, S, Floros, S, Fotiadis, I, Goudevenos, I, Kardara, D, Karidis, C, Koliopoulos, N, Kremastinos, D, Lekakis, I, Manolis, A, Pyrgakis, V, Papanikolaou, C, Papasteriadis, E, Skoufas, P, Stravrati, A, Stavridis, A, Syribeis, S, Vardas, P, Vassiliadis, I, Voudris, V, Zobolos, S, Berenyi, I, Edes, I, Janosi, A, Kalo, E, Karpati, P, Kornel, S, Pap, I, Polak, G, Reiber, I, Rusznak, M, Tarjan, J, Timar, S, Toth, K, Barton, J, Crean, P, Daly, K, Kearney, P, Meany, TB, Quigley, P, Antolini, R, Azzolini, P, Bellone, E, Branzi, A, Brunelli, C, Capponi, E, Capucci, A, Casaccia, M, Cecchetti, E, Ceci, V, Celegon, L, Colombo, A, Corsini, G, Cucchini, F, Dalla Volta, S, De Caterina, R, De Luca, I, De Servi, S, Di Donato, M, Di Giacomo, U, Di Pasquale, G, Fiorentini, C, Gaddi, O, Giannetto, M, Giannuzzi, P, Giordano, A, Giovannini, E, Guarnierio, M, Iacono, A, Inama, G, Leghissa, R, Lorusso, R, Marinoni, G, Marzilli, M, Mauri, F, Mosele, GM, Papi, S, Pela', G, Pettinati, G, Polimeni, MR, Portaluppi, F, Proto, C, Renaldini, E, Riva, S, Sanguinetti, M, Santini, M, Severi, S, Sinagra, G, Tantalo, L, Vajola, SF, Volterrani, M, Ansmite, B, Gailiss, E, Gersamija, A, Ozolina, MA, Baubiniene, A, Berukstis, E, Grigoniene, L, Kibarskis, A, Kirkutis, A, Marcinkus, R, Milvidaite, I, Vasiliauskas, D, Aalders, JCA, Bruggeling, WAJ, De Feyter, PJ, De Leeuw, MJ, De Waard, DEP, De Weerd, GJ, De Zwaan, C, Dijkgraaf, R, Droste, HT, Freericks, MP, Hagoort-Kok, AW, Hillebrand, F, Jap, WTJ, Jochemsen, GM, Kiemeney, F, Kuijer, PJP, Mannaerts, HFJ, Piek, JJ, Saelman, JPM, Slob, FD, Smits, WCG, Suttorp, MJ, Tan, TB, Van Beek, GJ, Van den Merkhof, LFM, Van der Heyden, R, Van Hessen, MWJ, Van Langeveld, RAM, Van Nierop, PR, Van Rey, FJW, Van Straalen, MJ, Vos, J, Werner, HA, Westendorp, JJC, Achremczyk, P, Adamus, J, Baska, J, Bolinska-Soltysiak, H, Bubinski, R, Ceremuzynski, L, Cieslinski, A, Dariusz, D, Drozdowski, P, Dubiel, JS, Galewicz, M, Halawa, B, Janion, M, Jaworska, K, Kaszewska, I, Kleinrok, A, Kornacewicz-Jach, Z, Krawczyk, W, Krynicki, R, Krzciuk, M, Krzeminska-Pakula, M, Kuch, J, Kuzniar, J, Liszewska-Pfejfer, D, Loboz-Grudzien, K, Musial, W, Opolski, G, Pasyk, S, Piwowarska, W, Pulkowski, G, Rynkiewicz, A, Sinkiewicz, W, Skura, M, Slowinski, S, Smielak-Korombel, W, Targonski, R, Templin, W, Tendera, M, Tracz, W, Trusz-Gluza, M, Wodniecki, J, Zalewski, M, Zinka, E, Carrageta, M, Gil, JC, Ferreira, R, Marques, AL, Andrade, CMS, Seabra-Gomes, R, Bada, V, Belicova, M, Dukat, A, Kaliska, G, Kamensky, G, Micko, K, Mikes, Z, Palinsky, M, Pella, D, Renker, B, Sefara, P, Sojka, G, Sulej, P, Szakacs, M, Salcedo, JMA, Orcajo, NA, Garcia, PA, Sanpera, JMA, Azcarate, JA, Mayor, JLB, Martinez, VB, Coronado, JLB, Ojeda, FB, Caimari, RB, Cortada, JB, Valderrama, JC, Ligorit, AD, Caliani, JSE, Aviles, FF, Guerrero, JJG, Lopez, DG, Cocina, EG, Urena, CG, Lorente, LJ, Garcia-Aranda, VL, De Miguel, CM, Montero, JM, Romero, PM, Benito, IM, Lopez, FN, Peiro, FN, De Ros, JO, Mas, JO, Bermejo, MAP, Peralta, LJP, Padial, LR, Sanz, AS, Bonnin, JS, Martin, ES, Belsue, FV, Ekdahl, S, Forslund, L, Ohlin, H, Pieper, M, Moccetti, T, Acartürk, E, Guzelsoy, D, Özsaruhan, O, Turkoglu, C, Adgey, AAJ, Ahsan, A, Al-Khafaji, M, Ball, SG, Birkhead, J, Boon, N, Brack, M, Bridges, A, Buchalter, M, Calder, B, Cooke, RA, Corr, L, Cowell, R, Curzen, NP, Davidson, C, Davies, J, De Belder, MA, Dhiya, L, Doig, JC, Findlay, IN, Francis, CM, Glancy, JM, Greenwood, TW, Groves, P, Hall, AS, Hamilton, G, Haq, I, Hillman, R, Hubbard, W, Hudson, I, Hutton, I, Ilsley, C, Innes, M, James, M, Jennings, K, Johnston, G, Jones, CJH, Joy, M, Keeling, P, Kooner, J, Lawson, C, Levy, RD, Lip, G, Mclachlan, B, Montgomery, HE, Morley, CA, Murdoch, DL, Muthusamy, R, Oakley, GDG, Penny, W, Percival, R, Purvis, J, Pye, MP, Ramsdale, D, Roberts, DH, Rozkovec, A, Salmassi, AM, Saltissi, S, Sardar, S, Shapiro, LM, Schofield, PM, Stephens, J, Shakespeare, C, Srivastava, S, Swan, JW, Tildesley, G, Travill, C, Wilkinson, PR, Fratacci, MD, Lerebours, G, Deckers, J

المساهمون: Fox, Km, Bertrand, M, Ferrari, R, Remme, Wj, Simoons, Ml, Simoons, M, Bassand, Jp, Aldershvile, J, Hildebrandt, P, Cokkinos, D, Toutouzas, P, Eha, J, Erhardt, L, Erikssen, J, Grybauskas, P, Kalnins, U, Karsch, K, Sechtem, U, Keltai, M, Klein, W, Lüscher, T, Mulcahy, D, Nieminen, M, Oto, A, Ozsaruhan, O, Paulus, W, Providencia, L, Riecansky, I, Ruzyllo, W, Santini, U, Tavazzi, L, Soler-Soler, J, Widimsky, P, Julian, D, Dargie, H, Murray, G, Kübler, W, Thygesen, K, Duprez, D, Steg, G, Drexel, H, Gombotz, G, Heyndrickx, Gh, Legrand, V, Materne, P, Van Mieghem, W, Bocek, P, Branny, M, Cech, M, Charouzek, J, Drazka, J, Fabik, L, Florian, J, Francek, L, Groch, L, Havranek, P, Hradec, J, Jansky, P, Jirmar, R, Jokl, I, Krejcova, H, Kvasnak, M, Maratka, T, Marcinek, G, Moravcova, J, Nedbal, P, Peterka, K, Povolny, J, Rosolova, H, Semrad, B, Sochor, K, Spacek, R, Spinar, J, Stipal, R, Stuchlik, K, Sulda, M, Ulman, J, Vaclavicek, A, Vojtisek, P, Bjerregaard-Andersen, H, Kristensen, K, Madsen, Jk, Markenvard, J, Meibom, J, Norgaard, A, Scheibel, M, Leht, A, Teesalu, R, Vahula, V, Itkonen, A, Juvonen, J, Karmakoski, J

الوصف: Background Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and those at high risk of such events. We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population with stable coronary heart disease and no apparent heart failure.Methods We recruited patients from October, 1997, to June, 2000. 13 655 patients were registered with previous myocardial infarction (64%), angiographic evidence of coronary artery disease (61%), coronary revascularisation (55%), or a positive stress test only (5%). After a run-in period of 4 weeks, in which all patients received perindopril, 12 218 patients were randomly assigned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108). The mean follow-up was 4.2 years, and the primary endpoint was cardiovascular death, myocardial infarction, or cardiac arrest. Analysis was by intention to treat.Findings Mean age of patients was 60 years (SD 9), 85% were male, 92% were taking platelet inhibitors, 62% beta blockers, and 58% lipid-lowering therapy. 603 (10%) placebo and 488 (8%) perindopril patients experienced the primary endpoint, which yields a 20% relative risk reduction (95% CI 9-29, p=0.0003) with perindopril. These benefits were consistent in all predefined subgroups and secondary endpoints. Perindopril was well tolerated.Interpretation Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome. About 50 patients need to be treated for a period of 4 years to prevent one major cardiovascular event. Treatment with perindopril, on top of other preventive medications, should be considered in all patients with coronary heart disease.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000185188500011; volume:362; issue:9386; firstpage:782; lastpage:788; numberofpages:7; journal:THE LANCET; https://hdl.handle.net/11381/2965992Test

الإتاحة: https://hdl.handle.net/11381/2965992Test

المؤلفون: Austria—h, Drexel, Gombotz, G., Belgium—d Duprez, W. K. L. E. I. N., Heyndrickx, G. H., Legrand, V., Materne, P., Czech Republic—p Bocek, W. Van M. I. E. G. H. E. M., Branny, M., Cech, M., Charouzek, J., Drazka, J., Fabik, L., Florian, J., Francek, L., Groch, L., Havranek, P., Hradec, J., Jansky, P., Jirmar, R., Jokl, I., Krejcova, H., Kvasnak, M., Maratka, T., Marcinek, G., Moravcova, J., Nedbal, P., Peterka, K., Povolny, J., Rosolova, H., Semrad, B., Sochor, K., Spacek, R., Spinar, J., Stipal, R., Stuchlik, K., Sulda, M., Ulman, J., Vaclavicek, A., Denmark—h Bjerregaard andersen, P. V. O. J. T. I. S. E. K., Hildebrandt, P., Kristensen, K., Madsen, J. K., Markenvard, J., Meibom, J., Norgaard, A., Estonia—j Eha, M. S. C. H. E. I. B. E. L., Leht, A., Teesalu, R., Finland—a Itkonen, V. V. A. H. U. L. A., Juvonen, J., Karmakoski, J., Kilkki, E., Koskela, E., Melin, J., Nieminen, M. S., Savola, R., Terho, T., France—f Apffel, L. M. V. O. I. P. I. O. . P. U. L. K. K. I., Attali, P., Barjhoux, C., Baron, B., Bassand, J. P., Berthier, Y., Dambrine, P., Decoulx, E., Deshayes, P., Fouche, R., Genest, M., Godard, S., Guillot, J. P., Hanania, G., Khattar, P., Leroy, F., Mansourati, J., Piquemal, R., Quiret, J. C., Raynaud, P., Rondepierre, D., Roynard, J. L., Sudhibhasilp, S., Germany—a Bilbal, E. Van B. E. L. L. E., Lauer, B., Rettig stürmer, G., Riessen, R., Rutsch, W., Sechtem, U., Sigel, H. A., Simon, R., Von Schacky, C., Greece—c Avgeropoulou, B. R. W. I. N. K. E. L. M. A. N. N., Christakos, S., Feggos, S., Floros, S., Fotiadis, I., Goudevenos, I., Kardara, D., Karidis, C., Koliopoulos, N., Kremastinos, D., Lekakis, I., Manolis, A., Pyrgakis, V., Papanikolaou, C., Papasteriadis, E., Skoufas, P., Stravrati, A., Stavridis, A., Syribeis, S., Vardas, P., Vassiliadis, I., Voudris, V., Hungary—i Berenyi, S. Z. O. B. O. L. O. S., Edes, I., Janosi, A., Kalo, E., Karpati, P., Kornel, S., Pap, I., Polak, G., Reiber, I., Rusznak, M., Tarjan, J., Timar, S., Ireland—j Barton, K. T. O. T. H., Crean, P., Daly, K., Kearney, P., Meany, T. B., Mulcahy, D., Italy—r Antolini, P. Q. U. I. G. L. E. Y., Azzolini, P., Bellone, E., Branzi, A., Brunelli, C., Capponi, E., Capucci, A., Casaccia, M., Cecchetti, E., Ceci, V., Celegon, L., Colombo, A., Corsini, G., Cucchini, F., Dalla Volta, S., De Caterina, R., De Luca, I., De Servi, S., Di Donato, M., Di Giacomo, U., Di Pasquale, G., Fiorentini, C., Gaddi, O., Giannetto, M., Giannuzzi, P., Giordano, A., Giovannini, E., Guarnierio, M., Iacono, A., Inama, G., Leghissa, R., Lorusso, R., Marinoni, G., Marzilli, M., Mauri, F., Mosele, G. M., Papi, S., Pettinati, G., Polimeni, M. R., Portaluppi, F., Proto, C., Renaldini, E., Riva, S., Sanguinetti, M., Santini, M., Severi, S., Sinagra, G., Tantalo, L., Tavazzi, L., Vajola, S. F., Latvia—b Ansmite, M. V. O. L. T. E. R. R. A. N. I., Gailiss, E., Gersamija, A., Kalnins, U., Lithuania—a Baubiniene, M. A. O. Z. O. L. I. N. A., Berukstis, E., Grigoniene, L., Kibarskis, A., Kirkutis, A., Marcinkus, R., Milvidaite, I., Aalders, D. V. A. S. I. L. I. A. U. S. K. A. S. Netherlands—j C. A., Bruggeling, W. A. J., De Feyter, P. J., De Leeuw, M. J., De Waard, D. E. P., De Weerd, G. J., De Zwaan, C., Dijkgraaf, R., Droste, H. T., Freericks, M. P., Hagoort kok, A. W., Hillebrand, F., Jap, W. T. J., Jochemsen, G. M., Kiemeney, F., Kuijer, P. J. P., Mannaerts, H. F. J., Piek, J. J., Saelman, J. P. M., Slob, F. D., Smits, W. C. G., Suttorp, M. J., Tan, T. B., Van Beek, G. J., Van Den Merkhof, L. F. M., Van Der Heyden, R., Van Hessen, M. W. J., Van Langeveld, R. A. M., Van Nierop, P. R., Van Rey, F. J. W., Van Straalen, M. J., Vos, J., Werner, H. A., Poland—p Achremczyk, J. J. C. W. E. S. T. E. N. D. O. R. P. Norway—j E. R. I. K. S. S. E. N., Adamus, J., Baska, J., Bolinska soltysiak, H., Bubinski, R., Ceremuzynski, L., Cieslinski, A., Dariusz, D., Drozdowski, P., Dubiel, J. S., Galewicz, M., Halawa, B., Janion, M., Jaworska, K., Kaszewska, I., Kleinrok, A., Kornacewicz jach, Z., Krawczyk, W., Krynicki, R., Krzciuk, M., Krzeminska pakula, M., Kuch, J., Kuzniar, J., Liszewska pfejfer, D., Loboz grudzien, K., Musial, W., Opolski, G., Pasyk, S., Piwowarska, W., Pulkowski, G., Ruzyllo, W., Rynkiewicz, A., Sinkiewicz, W., Skura, M., Slowinski, S., Smielak korombel, W., Targonski, R., Templin, W., Tendera, M., Tracz, W., Trusz gluza, M., Wodniecki, J., Zalewski, M., Portugal—m Carrageta, E. Z. I. N. K. A., Coelho Gil, J., Ferreira, R., Leitao Marques, A., Santos Andrade, C. M., Slovakia—v Bada, R. S. E. A. B. R. A. . G. O. M. E. S., Belicova, M., Dukat, A., Kaliska, G., Kamensky, G., Micko, K., Mikes, Z., Palinsky, M., Pella, D., Renker, B., Riecansky, I., Sefara, P., Sojka, G., Sulej, P., Aguirre Salcedo, M. S. Z. A. K. A. C. S. Spain—j M., Alonso Orcajo, N., Ancillo Garcia, P., Auge Sanpera, J. M., Ayuela Azcarate, J., Bardaji Mayor, J. L., Bertomeu Martinez, V., Blanco Coronado, J. L., Bosa Ojeda, F., Bros Caimari, R., Bruguera Cortada, J., Caparros Valderrama, J., Del Rio Ligorit, A., Espinosa Caliani, J. S., Fernandez Aviles, F., Garcia Guerrero, J. J., Garcia Lopez, D., Gonzalez Cocina, E., Guallar Urena, C., Jodar Lorente, L., Lopez Garcia aranda, V., Macaya De Miguel, C., Maroto Montero, J., Martinez Romero, P., Mate Benito, I., Navarro Lopez, F., Noriega Peiro, F., Olague De Ros, J., Orellana Mas, J., Paz Bermejo, M. A., Placer Peralta, L. J., Rodriguez Padial, L., Salvador Sanz, A., Segui Bonnin, J., Simarro Martin, E., Sweden—s Ekdahl, F. Valles B. E. L. S. U. E., Erhardt, L., Forslund, L., Switzerland—m Pieper, H. O. H. L. I. N., Turkey—e Acartürk, T. M. O. C. C. E. T. T. I., Guzelsoy, D., Oto, A., Özsaruhan, O., Adgey, C. T. U. R. K. O. G. L. U. Uk—a A. J., Ahsan, A., Al khafaji, M., Ball, S. G., Birkhead, J., Boon, N., Brack, M., Bridges, A., Buchalter, M., Calder, B., Cooke, R. A., Corr, L., Cowell, R., Curzen, N. P., Davidson, C., Davies, J., De Belder, M. A., Dhiya, L., Doig, J. C., Findlay, I. N., Fox, K. M., Francis, C. M., Glancy, J. M., Greenwood, T. W., PELA', Giovanna Maria

المساهمون: Austria—h, Drexel, Gombotz, G., Belgium—d Duprez, W. K. L. E. I. N., Heyndrickx, G. H., Legrand, V., Materne, P., Czech Republic—p Bocek, W. Van M. I. E. G. H. E. M., Branny, M., Cech, M., Charouzek, J., Drazka, J., Fabik, L., Florian, J., Francek, L., Groch, L., Havranek, P., Hradec, J., Jansky, P., Jirmar, R., Jokl, I., Krejcova, H., Kvasnak, M., Maratka, T., Marcinek, G., Moravcova, J., Nedbal, P., Peterka, K., Povolny, J., Rosolova, H., Semrad, B., Sochor, K., Spacek, R., Spinar, J., Stipal, R., Stuchlik, K., Sulda, M., Ulman, J., Vaclavicek, A., Denmark—h Bjerregaard andersen, P. V. O. J. T. I. S. E. K., Hildebrandt, P., Kristensen, K., Madsen, J. K., Markenvard, J., Meibom, J., Norgaard, A., Estonia—j Eha, M. S. C. H. E. I. B. E. L., Leht, A., Teesalu, R., Finland—a Itkonen, V. V. A. H. U. L. A., Juvonen, J., Karmakoski, J., Kilkki, E., Koskela, E., Melin, J., Nieminen, M. S., Savola, R., Terho, T., France—f Apffel, L. M. V. O. I. P. I. O. . P. U. L. K. K. I., Attali, P., Barjhoux, C., Baron, B., Bassand, J. P., Berthier, Y., Dambrine, P., Decoulx, E., Deshayes, P., Fouche, R., Genest, M., Godard, S., Guillot, J. P., Hanania, G., Khattar, P., Leroy, F., Mansourati, J., Piquemal, R., Quiret, J. C., Raynaud, P., Rondepierre, D., Roynard, J. L., Sudhibhasilp, S., Germany—a Bilbal, E. Van B. E. L. L. E., Lauer, B., Rettig stürmer, G., Riessen, R., Rutsch, W., Sechtem, U., Sigel, H. A., Simon, R., Von Schacky, C., Greece—c Avgeropoulou, B. R. W. I. N. K. E. L. M. A. N. N., Christakos, S., Feggos, S., Floros, S., Fotiadis, I., Goudevenos, I., Kardara, D., Karidis, C., Koliopoulos, N., Kremastinos, D., Lekakis, I.

الوصف: Background Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and those at high risk of such events. We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population with stable coronary heart disease and no apparent heart failure. Methods We recruited patients from October, 1997, to June, 2000. 13 655 patients were registered with previous myocardial infarction (64%), angiographic evidence of coronary artery disease (61%), coronary revascularisation (55%), or a positive stress test only (5%). After a run-in period of 4 weeks, in which all patients received perindopril, 12 218 patients were randomly assigned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108). The mean follow-up was 4·2 years, and the primary endpoint was cardiovascular death, myocardial infarction, or cardiac arrest. Analysis was by intention to treat. Findings Mean age of patients was 60 years (SD 9), 85% were male, 92% were taking platelet inhibitors, 62% β blockers, and 58% lipid-lowering therapy. 603 (10%) placebo and 488 (8%) perindopril patients experienced the primary endpoint, which yields a 20% relative risk reduction (95% Cl 9–29, p=0·0003) with perindopril. These benefits were consistent in all predefined subgroups and secondary endpoints. Perindopril was well tolerated. Interpretation Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome. About 50 patients need to be treated for a period of 4 years to prevent one major cardiovascular event. Treatment with perindopril, on top of other preventive medications, should be considered in all patients with coronary heart disease.

العلاقة: volume:362; firstpage:782; lastpage:788; numberofpages:7; journal:THE LANCET; http://hdl.handle.net/11381/2834366Test

الإتاحة: http://hdl.handle.net/11381/2834366Test

المؤلفون: Schulman, Sam, Kearon, Clive, Kakkar, Ajay K., Schellong, Sebastian, Eriksson, Henry, Baanstra, David, Kvamme, Anne Mathilde, Friedman, Jeffrey, Mismetti, Patrick, Goldhaber, Samuel Z. Schulman S, Eriksson H, Goldhaber S, Kakkar A, Kearon C, Mismetti P, Schellong S, Minar E, Bergqvist D, Tijssen J, Prins M, Büller H, Otten J, Mac Gillavry M, Brandjes D, Otten H, Peters R, Pol S, Burroughs A, Gilmore I, Bluguermann J, Bustos B, Carlevaro O, Cartasegna L, Cuello J, Gabito A, Gitelman P, Gutierrez Carrillo N, Hrabar A, Mackinon I, Santos D, Schygiel P, Sosa Liprandi M, Baker R, Blombery P, Gallus A, Gan E, McCann A, Salem H, Koppensteiner R, Kyrle P, Pilger E, Sturm W, Hainaut P, Verhamme P, Wautrecht JC, Zicot M, Bizzachi J, Joyce M, Araújo G, de Araújo Filho J, Panico M, Pereira A, Rocha Moreira R, Timi J, Yamashita E, Anastasov V, Georgiev G, Guirov K, Lozev I, Milanov S, Peneva M, Petrov V, Yordanov Y, Anderson D, Crowther M, Dolan S, Eikelboom J, Game M, Kahn S, Kassis J, Klinke P, Ritchie B, Rodger M, Solymoss S, Spencer F, Yeo E, Bai C, Liu C, Liu J, Shen H, Wan H, Wang C, Wang Y, Wen F, Ying K, Yuan Y, Zhang J, Zhang L, Zheng Q, Zhong N, Bercikova J, Cervinka P, Cizek V, Jirka V, Lang P, Maly R, Oral I, Prochazka P, Spinar J, Brønnum-Schou J, Friis E, Jensen S, Nielsen H, Skødebjerg Kristensen K, Wiemann O, Husted S, Kuusisto A, Lassila R, Melin J, Nikkilä M, Nousiainen T, Bost V, Buchmuller A, Guillot K, Lecomte F, Mottier D, Wahl D, Beyer-Westendorf J, Dormann A, Harenberg J, Hoffmann U, Maier M, Mietaschk A, Salbach P, Cohen A, Keeling D, Kesteven P, Maclean MR, Shah P, Katsenis K, Klonaris C, Liappis C, Mihailidis D, Acsady G, Boda Z, Farkas K, Jakucs J, Kollar L, Matyas L, Muranyi A, Riba M, Sereg M, Banker D, Durairaj N, Gadkari M, Grant P, Hiremath J, Kareem S, Mahajan R, Naik A, Parakh R, Rai K, Santhosh M, Sekar N, Srinivas A, Suresh K, Vijayaraghavan G, Brenner B, Efrati S, Mazen E, Gavish D, Grossman E, Lahav M, Lishner M, Lugassy G, Zeltser D, Barillari G, D' Angelo A, Palareti G, Santonasto M, Schenone A, Silingardi M, Testa S, Aldrett Lee E, Fontes Andrade J, Jaurrieta Valles J, Montaño-González E, Sánchez-Escalante LR, Dees A, Hamulyak K, Jie A, Kamphuisen P, Leebeek F, Nurmohamed M, Pruijt J, Wittebol S, Hanna M, Jackson S, Ockelford P, Smith M, Njaastad A, Sandseth P, Tveit A, Waage A, Czarnobilski K, Gaciong Z, Gluszek S, Krolczyk J, Zawilska K, Barata J, Capitao M, e Fernandes F, Martinez J, Providência L, Sarmento P, Belentsov S, Chernyatina M, Chernyavsky A, Degterev M, Fokin A, Gubenko A, Guz V, Katelnitsky I, Khamitov A, Khitaryan A, Khubulava G, Koulikovsky V, Nelaev V, Shkurin V, Smirnov G, Sokurenko G, Soroka V, Staroverov I, Zaporozhsky S, Duris T, Poliacik P, Spisak V, Szentivanyi M, Zubek V, Adler D, Le Roux D, Routier R, Siebert R, Sloane B, Smith C, del Toro J, García-Fuster M, Marco P, Mateo J, Monreal M, Nieto J J, Sedano C, Trujillo J, Villalta J, Aagesen J, Carlsson A, Lärfars G, Lindmarker P, Säfwenberg U, Själander A, Aslim E, Bengisun U, Calkavur T, Eren E, Karahan S, Karatepe O, Kurtoglu M, Sakinci U, Gubka O, Karpovych D, Mishalov V, Skupyy O, Bartkowiak A Jr, Bolster E, Burnett B, Comerota A, Fulco F, Gleeson J, Gossage J, Kaatz S, Kuehl S, Lahiri B, Masson J, Moll S, Nathanson A, Paulson R, Powell R, Seibert A, Vrooman P, Sandgren G, Wallin J, Kälebo P, Angerås U, Falk A, Eriksson B, Dellborg M, Eriksson P, Johansson P, Hansson PO, Nicol A, Jeffries B, Benson M, Kyrle PA, Hirschl M, Böhler K, de Vleeschauwer P, Haerens M, Duchateau J, Verstraeten P, Milot A, Kotik L, Roztocil K, Joerg I, Holy M, Cernosek B, Kasalova Z, Mandakova E, Povolny J, Matoska P, Hulinsky V, Podoubsky R, Votocek S, Zarubova D, Ellervee T, Lind J, Sukles K, Uebel P, Bauersachs R, Kemkes-Matthes B, Beyer J, Siragusa S, Bova C, Cortellaro M, Falanga A, Palla A, Pini M, Poggio R, Porro F, Prisco D, Tiraferri E, Villalta S, Visona A, Zanatta N, Mazzucconi MG, Porreca E, Cattaneo M, Di Minno G, Oh D, Kim CS, Kwon TW, Lee TS, Park JS, Hong YS, Yoon SS, Kim YK, Laucevicius A, Miliauskas S, Novikovs N, Zvirgzdins V, Meijer K, Nijziel MR, van Guldener C, van Essen GG, Ouwehand ME, Jie KS, Swart-Heikens J, Viergever PP, Dullemond AC, Tomkowski W, Torbicki A, Psuja P, Staszkiewicz W, Szopinski P, Pruszczyk P, Ciostek P, Windyga J, Stepien J, Khamitov AA, Ng HJ, Elf J, Engquist L, Sharo S, Holmström M, Lapidus L, Cederin B, Brack T, Binkert M, Canova C, Franzeck U, Allmann JK, Zehnder T, Jeanneret C, Jäger K, Erni D, Banyai M, Rödel C, Engelbrecht J, Bruning A, van Rensburg H, Vermooten IH, Norasetthada L, Thungthong P, Angchaisuksiri P, Numbenjapon T, Cook R, Deck K, Evans B, Hearne S, Kaelin T, Kuno R, Pendelton R, Speer J, Yood R, Kahn R, Sheehan K, Feldman G, Chen YC, Fanning J, Hartley P, Kulback S, McIvor ME, LaPerna L, Gibson K, Vaid BR, Changlani M.

المساهمون: Schulman, Sam, Kearon, Clive, Kakkar, Ajay K., Schellong, Sebastian, Eriksson, Henry, Baanstra, David, Kvamme, Anne Mathilde, Friedman, Jeffrey, Mismetti, Patrick, Goldhaber, Samuel Z., Schulman S, Eriksson, H, Goldhaber, S, Kakkar, A, Kearon, C, Mismetti, P, Schellong, S, Minar, E, Bergqvist, D, Tijssen, J, Prins, M, Büller, H, Otten, J, Mac Gillavry, M, Brandjes, D, Otten, H, Peters, R, Pol, S, Burroughs, A, Gilmore, I, Bluguermann, J, Bustos, B, Carlevaro, O, Cartasegna, L, Cuello, J, Gabito, A, Gitelman, P, Gutierrez Carrillo, N, Hrabar, A, Mackinon, I, Santos, D, Schygiel, P, Sosa Liprandi, M, Baker, R, Blombery, P, Gallus, A, Gan, E, Mccann, A, Salem, H, Koppensteiner, R, Kyrle, P, Pilger, E, Sturm, W, Hainaut, P, Verhamme, P, Wautrecht, Jc, Zicot, M, Bizzachi, J, Joyce, M, Araújo, G, de Araújo Filho, J, Panico, M, Pereira, A, Rocha Moreira, R, Timi, J, Yamashita, E, Anastasov, V, Georgiev, G, Guirov, K, Lozev, I, Milanov, S, Peneva, M, Petrov, V, Yordanov, Y, Anderson, D, Crowther, M, Dolan, S, Eikelboom, J, Game, M, Kahn, S, Kassis, J, Klinke, P, Ritchie, B, Rodger, M, Solymoss, S, Spencer, F, Yeo, E, Bai, C, Liu, C, Liu, J, Shen, H, Wan, H, Wang, C, Wang, Y

مصطلحات موضوعية: Adolescent, Adult, Aged, 80 and over, Benzimidazole, Dabigatran, Female, Follow-Up Studie, Hemorrhage, Human, Intention to Treat Analysi, International Normalized Ratio, Male, Middle Aged, Recurrence, Risk, Venous Thromboembolism, Warfarin, Young Adult, beta-Alanine, Medicine (all)

الوصف: BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95% confidence interval [CI], 0.78 to 2.64; P=0.01 for noninferiority). Major bleeding occurred in 13 patients in the dabigatran group (0.9%) and 25 patients in the warfarin group (1.8%) (hazard ratio, 0.52; 95% CI, 0.27 to 1.02). Major or clinically relevant bleeding was less frequent with dabigatran (hazard ratio, 0.54; 95% CI, 0.41 to 0.71). Acute coronary syndromes occurred in 13 patients in the dabigatran group (0.9%) and 3 patients in the warfarin group (0.2%) (P=0.02). In the placebo-control study, recurrent venous thromboembolism occurred in 3 of 681 patients in the dabigatran group (0.4%) and 37 of 662 patients in the placebo group (5.6%) (hazard ratio, 0.08; 95% CI, 0.02 to 0.25; P<0.001). Major bleeding occurred in 2 patients in the dabigatran group (0.3%) and 0 patients in the placebo group. Major or clinically relevant bleeding occurred in 36 patients in the dabigatran group (5.3%) and 12 patients in the placebo group (1.8%) (hazard ratio, 2.92; 95% CI, 1.52 to 5.60). Acute coronary syndromes occurred in 1 patient each in the dabigatran and placebo groups. CONCLUSIONS: Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo. (Funded by Boehringer Ingelheim; RE-MEDY and RE-SONATE ClinicalTrials.gov numbers, ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/23425163; info:eu-repo/semantics/altIdentifier/wos/WOS:000315095800005; volume:368; issue:8; firstpage:709; lastpage:718; numberofpages:10; journal:NEW ENGLAND JOURNAL OF MEDICINE; http://hdl.handle.net/11564/692080Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84874003257

الإتاحة: https://doi.org/10.1056/NEJMoa1113697Test
http://hdl.handle.net/11564/692080Test

المؤلفون: Büller HR, Gallus AS, Prins MH, Raskob G, Decousus H, Charbonnier B, Leizorovicz A, Laporte S, Quenet S, Brandjes DP, Middeldorp S, Blüguermann J, Amuchastegui L, Ahuad Guerrero R, Oberti P, Alvarez C, Cassettari A, Santos D, Macin S, Santini F, Ward C, Coughlin P, Salem H, Gan E, Leyden M, Prosser I, Crispin P, Carroll P, Gallus A, McRae S, Waites J, Pilger E, Koppensteiner R, Kyrle P, Schinko H, Mrochek A, Mitkovskaya N, Prystrom A, Motte S, Ninane V, Delcroix M, Hainaut P, Schneider E, Saraiva J, Maia L, Barreto S, Fernandes Manenti E, Araujo G, Dutra O, Fiss E, Moreira R, Yankov K, Nenkova S, Ivanov Y, Kostov V, Bhargava R, Chan Y, Miron MJ, Cusson J, Ugarte S, Morales A, Andresen M, Lanas F, Arriagada G, Mendoza JJ, Zuñiga C, Sepulveda P, Wang C, Liu Z, Yuan Y, Ma Z, Fang B, Liu J, Bai C, Wu H, Yang L, Ying K, Kang J, Li Q, Cheng Z, Zhang J, Wang H, Xie C, Xia G, Du Y, Wu Q, Zhou X, Chen L, Yi Q, Wu C, Hao Q, Liu S, Xiong S, Jiang S, Zhao L, Xiao Q, Qin Z, Zhou J, Dennis R, Miserque N, Igueredo M, Londoño D, Hildebrando J, Granados M, Buitrago R, Solano MH, Pacheco Alvis PM, Botero R, Saenz O, Bergovec M, Padovan M, Vucic N, Samarzija M, Chlumsky J, Spacek R, Klimsa Z, Gregor P, Povolny J, Podpera I, Holm F, Lang P, Matoska P, Sabl P, Spinar J, Spac J, Husted S, Avnstrom S, Rasmussen S, Christensen A, Guindy R, Hassanein M, Paumets M, Meriste S, Ferrari E, Achkar A, Azarian R, Meneveau N, Lorut C, Mouallem J, Crestani B, Proton A, Salmeron S, Lerousseau L, Mottier D, Wahl D, Siafakas N, Papadimitriou D, Katis K, Katsaris G, Gaga A, Damianos A, Tipparaju S, Kalkunte S, Vidhut J, Kalashetti S, Mehta P, Talwar D, Ramanathan R, Mishra R, Zeltzer D, Lahav M, Brenner B, Caraco Y, Elias M, Piovella F, Barone M, Poggio R, Palla A, Ghirarduzzi A, Pini M, Lodigiani C, Agnelli G, Imberti D, Scannapieco G, Salvi A, Bautista E, Diaz J, Mercado R, Ranero A, Rodriguez D, Jerjes C, Villeda Espinoza E, Van Der Meer J, Ijfering W, Van Marwijk Kooy M, Boersma W, Van Leendert R, Kroon C, Dullemond Westland A, Viergever P, Kuipers A, Grootenboers M, Creemers J, Pieters W, De Munck D, Timmer H, Jackson S, Sandset P, Meyer P, Kristiansen T, Portugal J, Paz E, Salazar D, Chavez W, Castillo L, De Guia T, Lenora F, Tomkowski W, Kloczko J, Rybak Z, Gaciong Z, Sobkowicz B, Pruszczyk P, Nizankowski R, Mirek Bryniarska E, Kukla P, Reis A, França A, Cortez M, Sa J, Santos F, Marques MA, Gordeev I, Gendlin G, Yablonsky P, Sokurenko G, Soroka V, Lusov V, Markov V, Shvats Y, Katerlnitskiy I, Lapin O, Lyamina N, Subbotin Y, Kim I, Zilber E, Kchaisheva L, Poliacik P, Macek V, Pretorius JP, Abdullah I, Basson M, Bollinger C, Breedt J, Gani M, Jansen J, Le Roux G, Nortje H, Van Der Linder M, Van Zyl L, Viljoen J, Bruning A, Pujol Farriols R, Raguer E, Nuffal D, Sanchez Rodriguez A, Eriksson H, Almgren T, Carlsson A, Elf J, Olsson CG, Aagesen J, Savas I, Sahin A, Erdogan Y, Ozhan M, Ongen G, Celikel T, Turker H, Arseven O, Tuncay E, Ozacar R, Gudz I, Nykonenko O, Skupyy O, Kovalskyy I, Prasol V, Cohen A, Rodriguez Cintron W, Gurka D, Bradley J, Oliver G, Spyropoulos A, Lerner R, Fulmer J, Lu NP, Wright P, Han D, Servi R, Nadar V, Quaranta A, Gehring J, Ginsberg R, Jacobson A, Colan D, Vanway C, Gurza E, Braslow B, Shorr A, Rehm J, Martin J, Sellers M, Concha M, Gordon I, Pullman J, Moran J, Welker J, Panzarella P, Mullins M, Willms D, McGrew F, Turki M, Menajovsky L., PRANDONI, PAOLO

المساهمون: Büller, Hr, Gallus, A, Prins, Mh, Raskob, G, Decousus, H, Charbonnier, B, Leizorovicz, A, Laporte, S, Quenet, S, Brandjes, Dp, Middeldorp, S, Blüguermann, J, Amuchastegui, L, Ahuad Guerrero, R, Oberti, P, Alvarez, C, Cassettari, A, Santos, D, Macin, S, Santini, F, Ward, C, Coughlin, P, Salem, H, Gan, E, Leyden, M, Prosser, I, Crispin, P, Carroll, P, Mcrae, S, Waites, J, Pilger, E, Koppensteiner, R, Kyrle, P, Schinko, H, Mrochek, A, Mitkovskaya, N, Prystrom, A, Motte, S, Ninane, V, Delcroix, M, Hainaut, P, Schneider, E, Saraiva, J, Maia, L, Barreto, S, Fernandes Manenti, E, Araujo, G, Dutra, O, Fiss, E, Moreira, R, Yankov, K, Nenkova, S, Ivanov, Y, Kostov, V, Bhargava, R, Chan, Y, Miron, Mj, Cusson, J, Ugarte, S, Morales, A, Andresen, M, Lanas, F, Arriagada, G, Mendoza, Jj, Zuñiga, C, Sepulveda, P, Wang, C, Liu, Z, Yuan, Y, Ma, Z, Fang, B, Liu, J, Bai, C, Wu, H, Yang, L, Ying, K, Kang, J, Li, Q, Cheng, Z, Zhang, J, Wang, H, Xie, C, Xia, G, Du, Y, Wu, Q, Zhou, X, Chen, L, Yi, Q, Wu, C, Hao, Q, Liu, S, Xiong, S, Jiang, S, Zhao, L, Xiao, Q, Qin, Z, Zhou, J, Dennis, R, Miserque, N

الوصف: BACKGROUND: Treatment of pulmonary embolism with low-molecular-weight heparin and vitamin K antagonists, such as warfarin, is not ideal. We aimed to assess non-inferiority of idrabiotaparinux, a reversible longlasting indirect inhibitor of activated factor X, to warfarin in patients with acute symptomatic pulmonary embolism. METHODS: In our randomised, double-blind, double-dummy, non-inferiority trial, we enrolled adults with objectively documented acute symptomatic pulmonary embolism attending 291 centres in 37 countries. We excluded patients who were pregnant, had active bleeding, kidney failure, or malignant hypertension, or were at high risk of death, bleeding, or adverse reactions to study drugs. We randomly allocated patients to receive 5-10 days' enoxaparin 1·0 mg/kg twice daily followed by subcutaneous idrabiotaparinux (starting dose 3·0 mg) or adjusted-dose warfarin (target international normalised ratio 2·0-3·0); regimens lasted 3 months or 6 months dependent on clinical presentation. Block randomisation was done with a central interactive computerised system, stratified by study centre and intended treatment duration. The primary efficacy outcome was recurrent venous thromboembolism at 99 days after randomisation. We estimated the odds ratio and 95% CI with a Mantel-Haenzsel χ(2) analysis (non-inferiority margin 2·0) in the intention-to-treat population. The main safety outcome was clinically relevant bleeding (major or non-major) in all patients at day 99. This study is registered with ClinicalTrials.gov, number NCT00345618. FINDINGS: Between Aug 1, 2006, and Jan 31, 2010, we enrolled 3202 patients aged 18-96 years. 34 (2%) of 1599 patients randomly allocated to receive enoxaparin-idrabiotaparinux and 43 (3%) of 1603 patients randomly allocated to receive enoxaparin-warfarin had recurrent venous thromboembolism (odds ratio 0·79, 95% CI 0·50-1·25; p(non-inferiority)=0·0001). 72 (5%) of 1599 patients in the enoxaparin-idrabiotaparinux group and 106 (7%) of 1603 patients in the enoxaparin-warfarin group ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/22130488; info:eu-repo/semantics/altIdentifier/wos/WOS:000299317700033; volume:379; issue:9811; firstpage:123; lastpage:129; numberofpages:7; journal:THE LANCET; http://hdl.handle.net/11577/3033800Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84855836270

الإتاحة: https://doi.org/10.1016/S0140-6736Test(11)61505-5
http://hdl.handle.net/11577/3033800Test

المؤلفون: JAMES WP, CATERSON ID, COUTINHO W, FINER N, VAN GAAL LF, MAGGIONI AP, TORP-PEDERSEN C, SHARMA AM, SHEPHERD GM, RODE RA, RENZ CL, James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Sharma AM, Torp-Pedersen C, Pepine C, Pocock S, Drexler H, Swedberg K, Sleight P, Armstrong P, Kerr D, Dagenais G, Brophy J, Avezum A, Bogaty P, Fabbri G, Galli M, Hildebrandt P, Mann J, Ostergren J, Sherman D, Zannad F, Colquhoun D, Hollanders G, Costa e Forti A, Cifkova R, Toubro S, Ziegler O, Scherbaum WA, Jordan J, Halmy L, Ferrannini E, Santini F, Gonzalez C, Narkiewicz K, Hancu N, Payer J, Pascual J, Wilding J, Campbell L, Carey D, Gerstman M, Karrasch J, Lefkovits J, Marks J, Marks S, Moses R, Phillips P, Proietto J, Roberts D, Roberts-Thomson P, Shaw J, Simpson R, Singh B, Singleton Jeffries W, Stuckey B, Boland J, Brohet C, Coucke F, Dendale P, Jouret G, Kolanowski J, Kutnowski M, Martens F, Muls E, Peiffer F, Penninckx H, Scheen A, Schoors D, Vaerenberg M, Van Cleemput J, Van Crombrugge P, Van Kuyk M, Verhaegen A, Wollaert B, de Albuquerque DC, Appolinario J, de Godoy Matos AF, Gross JL, Halpern A, Kerr Saraiva JF, Milagres R, Repetto G, Suplicy HL, Zanella MT, Bednarova J, Cepelak V, Cerny P, Hainer V, Havranek P, Homza M, Jansa P, Karlicek M, Kolesar J, Kotik I, Kucera D, Kuchar J, Kunc M, Kvapil M, Linhart A, Machova V, Matuska J, Oral I, Pavlas J, Pesatova S, Povolny J, Semrad B, Smetana K, Soucek M, Svacina S, Tesinsky P, Urbanek R, Wasserburger B, Zachoval R, Zahumensky E, Zidkova E, Astrup A, Dominguez H, Faber J, Hilderbrant P, Kober L, Perrild H, Richelsen B, Sogaard P, Svendsen OL, Urhammer S, Archambeaud F, Basdevant A, Borys JM, Bringer J, Brunetiere C, Charpentier G, Cocaul-André M, Dabadie H, Dubreuil A, Estour B, Gautier JF, Gibault T, Halimi S, Hespel JP, Issa Sayegh M, Krempf M, Laville M, Lecerf JM, Louvet JP, Penfornis A, Ritz P, Schlienger JL, Schmitt B, Valensi P, Baar M, Beermann J, Bock M, Boenner G, Dammann HG, Diehm C, Ditschuneit H, Gadow J, Gehlhar S, Gessner S, Guthersohn A, Hamann A, Hanefeld M, Hasenfuss G, Herzner A, Heun KC, Heufelder AE, Hohensee H, Jacob S, Krings P, Krätzig B, Krosse B, Lehmann RT, Mindt-Prüfert S, Maisch B, Pfeiffer AF, Richard F, Rose B, Schmidt E, Scholze J, Schreckenberg A, Stuebler P, Walter J, Wirth A, Wunderlich J, Abraham G, Altorjay A, Augusztin G, Csaszar A, Czuriga I, Dinnyes J, Gero L, Gyimesi A, Janosi A, Kovacs I, Liziczai I, Majtenyi A, Medvegy M, Nadhazi Z, Pados G, Polak G, Ronaszeki A, Sido Z, Simon K, Anzà C, Bevilacqua M, Bosello O, Chiariello M, Cordera R, Ferrari E, Frittitta L, Giorgino R, Liuzzi A, Malinverni C, Di Mario U, Melchionda N, Occhi G, Perticone F, Pinchera A, Pinelli G, Rovera G, Santeusanio F, Urbinati S, Alpizar-Salazar M, Carrillo-Ortega E, Fanghanel Salmon G, Laviada-Molina HA, Madero MA, Rodriguez G, Saldate C, Sanchez-Castillo CP, Violante RM, Wacher N, Zayas-Jaime FJ, Zuniga-Guajardo S, Adamiec R, Banasiak W, Chrusciel P, Derlaga B, Gebala A, Gessek J, Janik K, Janion M, Kalina Z, Kozlowski A, Kusnierz B, Majcher Z, Miekus P, Niegowska J, Okopien B, Ostrowska L, Pasowicz M, Piepiorka M, Pluta W, Polaszewska-Muszynska M, Ponikowski P, Pupek-Musialik D, Sawicki A, Sobocik H, Stankiewicz A, Szpajer M, Trojnar R, Tykarski A, Wrabec K, Wyrzkowski B, Zahorska-Markiewicz B, Zalewski M, Carrageta M, Mendes Pedro MM, Parente Martins LM, dos Santos L, Babes A, Creteanu G, Dan GA, Dragulescu SI, Graur M, Tirgoviste CI, Morosanu M, Mota M, Paveliu FS, Radoi M, Ranetti A, Totoian I, Andre I, Bugan V, Cencarik J, Csala L, Farsky S, Gonsorcik J, Kamensky G, Kmec J, Krahulec B, Kurian R, Macek V, Majercak I, Micko K, Mokan M, Riecansky I, Sojka G, Uhliar R, Urgeova L, Vancik J, Baro FM, Barrios Merino A, Borras JL, Caixas A, Cuatrecasas Cambra G, Dominguez Escribano JR, Duran Garcia S, Escobar-Jimenez L, Esteva de Antonio I, Formiguera Sala X, Garcia-Luna PP, Garcia Robles R, Gonzalez Albarran O, Hernandez-Mijares A, Martin Hidalgo A, Masmiquel Comas L, Morales Perez F, Moreno Esteban B, Pascual Izuel JM, Redon Mas J, Ricart W, Rubio MA, Ruilope LM, Salas-Salvado J, Terroba Larumbe M, Tinahones F, de la Torre Casares ML, Vidal Cortada J, Zuniga-Perez Lemaur M, Abdulhakim EE, Adler A, Barnett AH, Bodmer C, Campbell IW, Chowdhury T, Cleland J, Cook RC, Dinneen S, Donnachie H, Haslam DW, Hillis GS, Horne M, Howarth DJ, Hughes E, Jackson S, Jones SC, Jones TH, Kumar S, Lean M, Maroni J, McInnes G, Middleton A, Morris A, Newcombe G, O'Kane KP, Pavel IC, Pawa R, Perry C, Pitts C, Raja A, Reckless J, Robinson J, Sarmiento R, Soo SC, Taylor S, Thomas HO, Thomson MA, Wilkins M.

المساهمون: James, Wp, Caterson, Id, Coutinho, W, Finer, N, VAN GAAL, Lf, Maggioni, Ap, TORP-PEDERSEN, C, Sharma, Am, Shepherd, Gm, Rode, Ra, Renz, Cl, Van Gaal, Lf, Torp-Pedersen, C, Pepine, C, Pocock, S, Drexler, H, Swedberg, K, Sleight, P, Armstrong, P, Kerr, D, Dagenais, G, Brophy, J, Avezum, A, Bogaty, P, Fabbri, G, Galli, M, Hildebrandt, P, Mann, J, Ostergren, J, Sherman, D, Zannad, F, Colquhoun, D, Hollanders, G, Costa, e Forti A, Cifkova, R, Toubro, S, Ziegler, O, Scherbaum, Wa, Jordan, J, Halmy, L, Ferrannini, E, Santini, F, Gonzalez, C, Narkiewicz, K, Hancu, N, Payer, J, Pascual, J, Wilding, J, Campbell, L, Carey, D, Gerstman, M, Karrasch, J, Lefkovits, J, Marks, J, Marks, S, Moses, R, Phillips, P, Proietto, J, Roberts, D, Roberts-Thomson, P, Shaw, J, Simpson, R, Singh, B, Singleton Jeffries, W, Stuckey, B, Boland, J, Brohet, C, Coucke, F, Dendale, P, Jouret, G, Kolanowski, J, Kutnowski, M, Martens, F, Muls, E, Peiffer, F, Penninckx, H, Scheen, A, Schoors, D, Vaerenberg, M, Van Cleemput, J, Van Crombrugge, P, Van Kuyk, M, Verhaegen, A, Wollaert, B, de Albuquerque, Dc, Appolinario, J, de Godoy Matos, Af, Gross, Jl, Halpern, A, Kerr Saraiva, Jf, Milagres, R

الوصف: BACKGROUND: The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. METHODS: We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). RESULTS: The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. CONCLUSIONS: Subjects with preexisting cardiovascular ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/20818901; info:eu-repo/semantics/altIdentifier/wos/WOS:000281441500004; volume:363; firstpage:905; lastpage:917; numberofpages:13; journal:NEW ENGLAND JOURNAL OF MEDICINE; http://hdl.handle.net/11568/141621Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-77956284607

الإتاحة: https://doi.org/10.1056/NEJMoa1003114Test
http://hdl.handle.net/11568/141621Test

المؤلفون: Bauersachs, Rupert, Berkowitz, Scott D, Brenner, Benjamin, Buller, Harry R, Decousus, Hervé, Gallus, Alex S, Lensing, Anthonie W, Misselwitz, Frank, Prins, Martin H, Raskob, Gary E, Segers, Annelise, Verhamme, Peter, Wells, Phil, Agnelli, Giancarlo, Bounameaux, Henri, Cohen, Alexander, Davidson, Bruce L, Piovella, Franco, Schellong Sebastian, Agnelli G, Berkowitz S, Bounameaux H, Büller H, Cohen A, Gallus A, Lensing A, Misselwitz F, Peters G, Prins M, Raskob G, Schellong S, Bauersachs R, van Bellen B, Boda Z, Borris L, Brenner B, Brighton T, Chlumský Y, Davidson B, Decousus H, Eriksson H, Jacobson B, Kakkar A, Kwong YL, Lee LH, Meijer K, van der Meer J, Minar E, Monreal M, Piovella F, Sandset PM, Smith M, Tomkowski W, Verhamme P, Wang Y, Wells P, Brandjes D, Mac Gillavry M, Otten HM, Carlsson A, Laporte S, Schulman S, Muehlhofer E, Tewes M, Whatton J, Mueller K, Beckmann H, Pap AF, Spadari G, Peters-Wulf C, Kubitza D, Muck W, Coughlin P, Chong B, Carroll P, Connors G, Baker R, Gan E, Leyden M, Crispin P, Ward C, Bianchi A, Leahy M, Blombery P, Campbell P, Dean M, Jackson D, Denaro C, Hirschl M, Baghestanian M, Mathies R, Pilger E, Marschang P, Vossaert R, Hainaut P, Motte S, Verhaeghe R, Vandekerkhof J, Vleeschauwer P, de Leersnyder J, Demelenne J, Buche M, Vermassen F, Sprynger M, Moreira R, Costa J, Sacilotto R, Silvestre J, Yoshida W, Panico M, Wolosker N, Kovacs M, Wong T, Selby R, Geerts W, Blondal J, Chen Z, Zhang J, Liu C, Dong Y, Guo W, Wu D, Ying K, Li X, Jin B, Xu J, Jing Z, Liu Z, Kovarova K, Spacek R, Podpera I, Patek F, Vitovec M, Chlumský J, Matoška P, Husted S, Tuxen C, Hildebrandt P, Nielsen H, Aquilanti S, Pernod G, Lacroix P, Schmidt J, Brisot D, Quere I, Mottier D, Stephan D, Achkar A, Boccalon H, Simoneau G, Lorenzini JL, Trinh-Duc A, Mahe I, Elias A, Emmerich J, Meneveau N, Roy PM, Vital-Durand D, Constans J, Le Jeunne C, Agraou B, Ferrari E, Meyer G, Potel G, Parent F, Sevestre MA, Franke D, Petermann W, Beyer-Westendorf J, Diehm C, Baron Von Bilderling P, Hoffmann U, Hasslacher C, Landgraf H, Horacek T, Lindhoff-Last E, Heckmann F, Mondorf W, Espinola-Klein C, Haering HU, Kieback A, Taute BM, Eifrig B, Potratz J, Herrmann T, Röcken M, Tse E, Kovács A, Sipos G, Farkas K, Gurzo M, Riba M, Landi A, Pécsvárady Z, Parakh R, Ramakrishna P, Sudhindran S, Kamerkar D, Sembiring R, Soeharti C, Tambunan K, Sumantri R, Zeltser D, Elias M, Hoffman R, Lishner M, Gavish D, Hussein O, Lugassy G, Varon D, Inbal A, Zisman D, Schliamser L, Haran M, Ghirarduzzi A, Barone M, Beltrametti C, Imberti D, Prandoni P, Porreca E, Di Nisio M, Martinelli I, Siragusa S, Ageno W, Ambrosio G, Palareti G, D'Angelo A, Quintavalla R, Cattaneo M, Park KH, Cho WH, Sathar J, Meier K, van Marwijk-Kooy M, Beeker A, Komdeur R, Kamphuisen PW, Groot M, Ten Cate H, Ockelford P, Simpson D, Harper P, Royle G, Beasley R, Quist-Paulsen P, Ghanima W, Tveit A, Abola M, Roxas D, Chęciński P, Adamiec R, Kloczko J, Witkiewicz W, Wronski J, Musial J, Oszkinis G, Strzelczyk J, Szyber P, Jackowski M, Ng J, Tay C, Becker J, Isaacs R, Adler D, Siebert R, van Zyl L, Wright N, van Marle J, Ellis G, Schmidt S, Villalta J, García-Bragado F, Sanchez J, Fontcuberta J, Aagesen J, Jonson T, Själander A, Mazzolai L, Banyai M, Frank U, Reinhardt W, Dorffler-Melly J, Asmis L, Chiu KM, Tsai W, Yu TJ, Angchaisuksiri P, Rojnuckarin P, Hunt B, Nokes T, Sekhar M, Dexter J, Lyons R, Nadar V, Krell K, Rehm J, Rathbun S, Spyropoulos A, Moll S, Chen D, Banish D, Joseph S, Rodgers G, Stevens S, Wright P, Botnick W, Albrecht C, Jaffer A, Kennedy M, Rodriguez W, McRae S, Kyrle PA, Forstner K, Soffiatti R, Wang C, Povolny J, Nielsen HK, Wahl D, Harenberg J, von Schwaiblmair W, Sembiring RJ, D'Angelo, Baresne M, Di Minno G, van Marwijk Kooy M, Mol J, Abola MT, Roxas DJ, Strzelczyk K, Lewczuk J, Ng HJ, Tay JC, Becker JH, Siebert RS, Redondo M, de Diego I, Grau E, Lapidus L, Wallen T, Luckit J, Cymet T.

المساهمون: Bauersachs, Rupert, Berkowitz, Scott D, Brenner, Benjamin, Buller, Harry R, Decousus, Hervé, Gallus, Alex S, Lensing, Anthonie W, Misselwitz, Frank, Prins, Martin H, Raskob, Gary E, Segers, Annelise, Verhamme, Peter, Wells, Phil, Agnelli, Giancarlo, Bounameaux, Henri, Cohen, Alexander, Davidson, Bruce L, Piovella, Franco, Schellong, Sebastian, Agnelli, G, Berkowitz, S, Bounameaux, H, Büller, H, Cohen, A, Gallus, A, Lensing, A, Misselwitz, F, Peters, G, Prins, M, Raskob, G, Schellong, S, Bauersachs, R, van Bellen, B, Boda, Z, Borris, L, Brenner, B, Brighton, T, Chlumský, Y, Davidson, B, Decousus, H, Eriksson, H, Jacobson, B, Kakkar, A, Kwong, Yl, Lee, Lh, Meijer, K, van der Meer, J, Minar, E, Monreal, M, Piovella, F, Sandset, Pm, Smith, M, Tomkowski, W, Verhamme, P, Wang, Y, Wells, P, Brandjes, D, Mac Gillavry, M, Otten, Hm, Carlsson, A, Laporte, S, Schulman, S, Muehlhofer, E, Tewes, M, Whatton, J, Mueller, K, Beckmann, H, Pap, Af, Spadari, G, Peters-Wulf, C, Kubitza, D, Muck, W, Coughlin, P, Chong, B, Carroll, P, Connors, G, Baker, R, Gan, E, Leyden, M, Crispin, P, Ward, C, Bianchi, A, Leahy, M, Blombery, P, Campbell, P, Dean, M, Jackson, D, Denaro, C, Hirschl, M, Baghestanian, M, Mathies, R, Pilger, E, Marschang, P, Vossaert, R, Hainaut, P, Motte, S, Verhaeghe, R

مصطلحات موضوعية: Acenocoumarol, Acute Disease, Administration, Oral, Aged, Anticoagulant, Double-Blind Method, Enoxaparin, Female, Hemorrhage, Human, Injections, Subcutaneou, Intention to Treat Analysi, Kaplan-Meier Estimate, Male, Middle Aged, Morpholine, Pulmonary Embolism, Rivaroxaban, Thiophene, Venous Thromboembolism, Venous Thrombosi, Vitamin K, Warfarin, Factor Xa Inhibitor, Medicine (all)

الوصف: BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring. METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. In parallel, we carried out a double-blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism. The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding or clinically relevant nonmajor bleeding in the initial-treatment study and major bleeding in the continued-treatment study. RESULTS: The study of rivaroxaban for acute DVT included 3449 patients: 1731 given rivaroxaban and 1718 given enoxaparin plus a vitamin K antagonist. Rivaroxaban had noninferior efficacy with respect to the primary outcome (36 events [2.1%], vs. 51 events with enoxaparin-vitamin K antagonist [3.0%]; hazard ratio, 0.68; 95% confidence interval [CI], 0.44 to 1.04; P<0.001). The principal safety outcome occurred in 8.1% of the patients in each group. In the continued-treatment study, which included 602 patients in the rivaroxaban group and 594 in the placebo group, rivaroxaban had superior efficacy (8 events [1.3%], vs. 42 with placebo [7.1%]; hazard ratio, 0.18; 95% CI, 0.09 to 0.39; P<0.001). Four patients in the rivaroxaban group had nonfatal major bleeding (0.7%), versus none in the placebo group (P=0.11). CONCLUSIONS: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/21128814; info:eu-repo/semantics/altIdentifier/wos/WOS:000285555600005; volume:363; issue:26; firstpage:2499; lastpage:2510; numberofpages:12; journal:NEW ENGLAND JOURNAL OF MEDICINE; http://hdl.handle.net/11564/692088Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-78650619315

الإتاحة: https://doi.org/10.1056/NEJMoa1007903Test
http://hdl.handle.net/11564/692088Test

المؤلفون: Büller, Hr, Gallus, As, Prins, Mh, Raskob, G, Decousus, H, Charbonnier, B, Leizorovicz, A, Laporte, S, Quenet, S, Brandjes, Dp, Middeldorp, S, Blüguermann, J, Amuchastegui, L, Ahuad Guerrero, R, Oberti, P, Alvarez, C, Cassettari, A, Santos, D, Macin, S, Santini, F, Ward, C, Coughlin, P, Salem, H, Gan, E, Leyden, M, Prosser, I, Crispin, P, Carroll, P, Gallus, A, Mcrae, S, Waites, J, Pilger, E, Koppensteiner, R, Kyrle, P, Schinko, H, Mrochek, A, Mitkovskaya, N, Prystrom, A, Motte, S, Ninane, V, Delcroix, M, Hainaut, P, Schneider, E, Saraiva, J, Maia, L, Barreto, S, Fernandes Manenti, E, Araujo, G, Dutra, O, Fiss, E, Moreira, R, Yankov, K, Nenkova, S, Ivanov, Y, Kostov, V, Bhargava, R, Chan, Y, Miron, Mj, Cusson, J, Ugarte, S, Morales, A, Andresen, M, Lanas, F, Arriagada, G, Mendoza, Jj, Zuñiga, C, Sepulveda, P, Wang, C, Liu, Z, Yuan, Y, Ma, Z, Fang, B, Liu, J, Bai, C, Wu, H, Yang, L, Ying, K, Kang, J, Li, Q, Cheng, Z, Zhang, J, Wang, H, Xie, C, Xia, G, Du, Y, Wu, Q, Zhou, X, Chen, L, Yi, Q, Wu, C, Hao, Q, Liu, S, Xiong, S, Jiang, S, Zhao, L, Xiao, Q, Qin, Z, Zhou, J, Dennis, R, Miserque, N, Igueredo, M, Londoño, D, Hildebrando, J, Granados, M, Buitrago, R, Solano, Mh, Pacheco Alvis PM, Botero, R, Saenz, O, Bergovec, M, Padovan, M, Vucic, N, Samarzija, M, Chlumsky, J, Spacek, R, Klimsa, Z, Gregor, P, Povolny, J, Podpera, I, Holm, F, Lang, P, Matoska, P, Sabl, P, Spinar, J, Spac, J, Husted, S, Avnstrom, S, Rasmussen, S, Christensen, A, Guindy, R, Hassanein, M, Paumets, M, Meriste, S, Ferrari, E, Achkar, A, Azarian, R, Meneveau, N, Lorut, C, Mouallem, J, Crestani, B, Proton, A, Salmeron, S, Lerousseau, L, Mottier, D, Wahl, D, Siafakas, N, Papadimitriou, D, Katis, K, Katsaris, G, Gaga, A, Damianos, A, Tipparaju, S, Kalkunte, S, Vidhut, J, Kalashetti, S, Mehta, P, Talwar, D, Ramanathan, R, Mishra, R, Zeltzer, D, Lahav, M, Brenner, B, Caraco, Y, Elias, M, Piovella, F, Barone, M, Poggio, R, Palla, A, Ghirarduzzi, A, Pini, M, Lodigiani, C, Prandoni, Paolo, Agnelli, G, Imberti, D, Scannapieco, G, Salvi, A, Bautista, E, Diaz, J, Mercado, R, Ranero, A, Rodriguez, D, Jerjes, C, Villeda Espinoza, E, Van Der Meer, J, Ijfering, W, Van Marwijk Kooy, M, Boersma, W, Van Leendert, R, Kroon, C, Dullemond Westland, A, Viergever, P, Kuipers, A, Grootenboers, M, Creemers, J, Pieters, W, De Munck, D, Timmer, H, Jackson, S, Sandset, P, Meyer, P, Kristiansen, T, Portugal, J, Paz, E, Salazar, D, Chavez, W, Castillo, L, De Guia, T, Lenora, F, Tomkowski, W, Kloczko, J, Rybak, Z, Gaciong, Z, Sobkowicz, B, Pruszczyk, P, Nizankowski, R, Mirek Bryniarska, E, Kukla, P, Reis, A, França, A, Cortez, M, Sa, J, Santos, F, Marques, Ma, Gordeev, I, Gendlin, G, Yablonsky, P, Sokurenko, G, Soroka, V, Lusov, V, Markov, V, Shvats, Y, Katerlnitskiy, I, Lapin, O, Lyamina, N, Subbotin, Y, Kim, I, Zilber, E, Kchaisheva, L, Poliacik, P, Macek, V, Pretorius, Jp, Abdullah, I, Basson, M, Bollinger, C, Breedt, J, Gani, M, Jansen, J, Le Roux, G, Nortje, H, Van Der Linder, M, Van Zyl, L, Viljoen, J, Bruning, A, Pujol Farriols, R, Raguer, E, Nuffal, D, Sanchez Rodriguez, A, Eriksson, H, Almgren, T, Carlsson, A, Elf, J, Olsson, Cg, Aagesen, J, Savas, I, Sahin, A, Erdogan, Y, Ozhan, M, Ongen, G, Celikel, T, Turker, H, Arseven, O, Tuncay, E, Ozacar, R, Gudz, I, Nykonenko, O, Skupyy, O, Kovalskyy, I, Prasol, V, Cohen, A, Rodriguez Cintron, W, Gurka, D, Bradley, J, Oliver, G, Spyropoulos, A, Lerner, R, Fulmer, J, Lu, Np, Wright, P, Han, D, Servi, R, Nadar, V, Quaranta, A, Gehring, J, Ginsberg, R, Jacobson, A, Colan, D, Vanway, C, Gurza, E, Braslow, B, Shorr, A, Rehm, J, Martin, J, Sellers, M, Concha, M, Gordon, I, Pullman, J, Moran, J, Welker, J, Panzarella, P, Mullins, M, Willms, D, Mcgrew, F, Turki, M, Menajovsky, L.

المساهمون: Epidemiologie, MUMC+: KIO Kemta (9), RS: CAPHRI School for Public Health and Primary Care, Amsterdam Cardiovascular Sciences, Vascular Medicine, Department of Vascular Medicine (DVM - AMC), Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA)-University of Amsterdam [Amsterdam] (UvA), SA Pathology at Flinders Medical Center (ASG), Flinders University, Department of Epidemiology (MHP), Maastricht University [Maastricht], College of Public Health (CPH), University of Oklahoma (OU), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO)

المصدر: Lancet, 379(9811), 123-129. Elsevier Science
Lancet, 379(9811), 123-129. Elsevier Limited
Lancet
Lancet, Elsevier, 2012, 379 (9811), pp.123-9. ⟨10.1016/S0140-6736(11)61505-5⟩

مصطلحات موضوعية: Male, MESH: Pulmonary Embolism, Oligosaccharides, MESH: Factor X, 030204 cardiovascular system & hematology, MESH: Intention to Treat Analysis, MESH: Aged, 80 and over, 0302 clinical medicine, MESH: Double-Blind Method, 030212 general & internal medicine, MESH: Warfarin, Aged, 80 and over, MESH: Aged, education.field_of_study, Idrabiotaparinux, MESH: Middle Aged, General Medicine, Heparin, Middle Aged, Intention to Treat Analysis, 3. Good health, Pulmonary embolism, Acute Disease, MESH: Acute Disease, Drug Therapy, Combination, Female, medicine.drug, Adult, medicine.medical_specialty, MESH: Enoxaparin, Adolescent, Population, Biotin, MESH: Anticoagulants, Double blind, 03 medical and health sciences, Double-Blind Method, Internal medicine, MESH: Biotin, medicine, Humans, Enoxaparin, education, Aged, MESH: Adolescent, MESH: Humans, Intention-to-treat analysis, business.industry, Warfarin, Anticoagulants, MESH: Adult, Odds ratio, medicine.disease, MESH: Male, Surgery, MESH: Drug Therapy, Combination, Factor X, Pulmonary Embolism, business, MESH: Female, MESH: Oligosaccharides, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology

الوصف: International audience; BACKGROUND: Treatment of pulmonary embolism with low-molecular-weight heparin and vitamin K antagonists, such as warfarin, is not ideal. We aimed to assess non-inferiority of idrabiotaparinux, a reversible longlasting indirect inhibitor of activated factor X, to warfarin in patients with acute symptomatic pulmonary embolism. METHODS: In our randomised, double-blind, double-dummy, non-inferiority trial, we enrolled adults with objectively documented acute symptomatic pulmonary embolism attending 291 centres in 37 countries. We excluded patients who were pregnant, had active bleeding, kidney failure, or malignant hypertension, or were at high risk of death, bleeding, or adverse reactions to study drugs. We randomly allocated patients to receive 5-10 days' enoxaparin 1*0 mg/kg twice daily followed by subcutaneous idrabiotaparinux (starting dose 3*0 mg) or adjusted-dose warfarin (target international normalised ratio 2*0-3*0); regimens lasted 3 months or 6 months dependent on clinical presentation. Block randomisation was done with a central interactive computerised system, stratified by study centre and intended treatment duration. The primary efficacy outcome was recurrent venous thromboembolism at 99 days after randomisation. We estimated the odds ratio and 95% CI with a Mantel-Haenzsel χ(2) analysis (non-inferiority margin 2*0) in the intention-to-treat population. The main safety outcome was clinically relevant bleeding (major or non-major) in all patients at day 99. This study is registered with ClinicalTrials.gov, number NCT00345618. FINDINGS: Between Aug 1, 2006, and Jan 31, 2010, we enrolled 3202 patients aged 18-96 years. 34 (2%) of 1599 patients randomly allocated to receive enoxaparin-idrabiotaparinux and 43 (3%) of 1603 patients randomly allocated to receive enoxaparin-warfarin had recurrent venous thromboembolism (odds ratio 0*79, 95% CI 0*50-1*25; p(non-inferiority)=0*0001). 72 (5%) of 1599 patients in the enoxaparin-idrabiotaparinux group and 106 (7%) of 1603 patients in the enoxaparin-warfarin group had clinically relevant bleeding (0*67, 0*49-0*91; p(superiority)=0*0098). We noted similar differences in outcomes in those patients treated to 6 months. INTERPRETATION: Idrabiotaparinux could provide an attractive alternative to warfarin for the long-term treatment of pulmonary embolism, and seems to be associated with reduced bleeding. FUNDING: Sanofi-Aventis (Paris, France).

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2cef81233461dd5dcb497955b4d24c6Test
https://cris.maastrichtuniversity.nl/en/publications/70fa0a5d-d76f-4e74-9002-0f44cf51ae9fTest